Latest News

BioMedPartners raise CHF75m fund

City skyline of Basel. © fotolia.com/ compuinfoto

Basel-based BioMedPartners announes the first round of BioMedInvest III, its third equity venture capital fund at CHF75m. Up to 16 private Swiss, German and EU early-to-midstage ventures might be selected in the first closing by Q1/2018.

 “We are delighted that the continued success of BioMedInvest convinced many of the major investors of the previous funds to commit also to BioMedInvest III. Among these are the European Investment Fund (EIF) on behalf of the ERP-EIF Dachfonds as cornerstone investor, and the Berner Kantonalbank, BEKB. In addition we could gain several important new private investors.” says Dr. Markus Hosang, General Partner at BioMedPartners.

„This is a major milestone for the future of the Swiss Life Science Cluster”, said Thomas Moeller, General Partner at BioMedPartners. “The expertise and successful investment track record that the BioMedPartners team brings to the table will enable it to translate innovative science into new companies, products and economic benefit and future growth,“ said Andreas Wallnöfer, formed Head of Clinical Research & Exploratory Development at F. Hoffmann- La- Roche AG, who now has become Partner at BioMedPartners. 

BioMedPartners’ BioMedInvest III, which has a target size of CHF120-150m, is not the only life sciences vertical coming up at the global life science hub Basel. BaselArea.swiss has announced it will officially launch another life sciences accelerator termed BaseLaunch in February. The accelerator, said to be supported by several Big Pharma partners, will offer full-range support for groundbreaking healthcare innovations that serve unmet medical need at the global life science hub.

According to the 2016 EU Industrial R&D Investment Scoreboard, the two Basel-based companies Novartis and Roche invest more in research and development than all other international pharmaceutical companies.